Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

With people gathering indoors in the cold weather, it can be easy to catch illnesses, and health officials are giving tips on ...

Video: Broad Institute of MIT and Harvard At a glance: Study explains long-standing question of why Huntington’s disease symptoms typically do not appear until midlife even though patients are born ...

Beta blockers were associated with later appearance of motor symptoms and slower symptom worsening, but an outside expert ...

Huntington’s disease symptoms are linked to expanding DNA repeats (CAG) that become toxic in brain cells over time The "ticking DNA clock" accelerates after 80 repeats, killing neurons within ...

A recent study published in Cell reveals that the repeated DNA sequence that leads to Huntington’s disease (HD) expands ...

STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics ("Atalanta" or "the Company").

This type of "somatic expansion" occurs in only the specific types of brain cells that later die in Huntington's disease ... numbers of these cells die, patients develop involuntary movements ...

Huntington’s disease ... however, that patients with mutations in their DNA-repair genes often showed unusually early or late onset of disease. These same DNA-repair genes were also shown ...

People genetically susceptible to Huntington's disease often see their movement, mood, and cognition decline slowly over time.

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link ... diseased brains from HD patients.